DESK REVIEWS | 06.02.09. Are there relevant sub-groups of specific dementias? What is their prevalence/incidence?

DESK REVIEW | 06.02.09. Are there relevant sub-groups of specific dementias? What is their prevalence/incidence?

No information was found on this topic.

The  prevalence of AIDS associated dementia is relatively low (1-2% of persons infected with HIV) in the Indian context (Ranga et al., 2004; Satischandra et al., 2000; Wadia et al., 2001).

References:

Ranga, U., Shankarappa, R., Siddappa, N. B., Ramakrishna, L., Nagendran, R., Mahalingam, M., Mahadevan, A., Jayasuryan, N., Satishchandra, P., Shankar, S. K., & Prasad, V. R. (2004). Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. Journal of virology78(5), 2586–2590. https://doi.org/10.1128/jvi.78.5.2586-2590.2004

Satishchandra, P., Nalini, A., Gourie-Devi, M., Khanna, N., Santosh, V., Ravi, V., … & Shankar, S. K. (2000). Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96). Indian Journal of Medical Research, 111, 14-23.

Wadia, R. S., Pujari, S. N., Kothari, S., Udhar, M., Kulkarni, S., Bhagat, S., & Nanivadekar, A. (2001). Neurological manifestations of HIV disease. The Journal of the Association of Physicians of India, 49, 343-348.

We found non data on the national prevalence or incidence of specific type of dementias.

There are no national statistics on HIV-related dementia in Kenya.

No data is yet available.

Due to the country’s high HIV/AIDS prevalence, HIV-associated dementia (HAD) is a potentially significant sub-group of dementias. The prevalence for HIV-Associated Neurocognitive Disorders (HAND) is estimated to range between 15-60% (between settings) (Mogambery et al., 2017).

References:

Mogambery, J. C., Dawood, H., Wilson, D., & Moodley, A. (2017). HIV-associated neurocognitive disorder in a KwaZulu-Natal HIV clinic: A prospective study. Southern African Journal of HIV Medicine, 18(1), 1–5. https://doi.org/10.4102/sajhivmed.v18i1.732